CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY AGENT

(19)

(11)

EP 2 229 185 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.12.2016 Bulletin 2016/51

(45)	Mention of the grant of the patent:
	07.10.2015 Bulletin 2015/41

(21)	Application number: 08859906.3

(22)	Date of filing: 02.12.2008

(51)

International Patent Classification (IPC):

A61K 47/42^(2006.01)

(86)	International application number:
	PCT/US2008/085280

(87)	International publication number:
	WO 2009/076105 (18.06.2009 Gazette 2009/25)

(54)

CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY AGENT

GLEICHZEITIGE VERABREICHUNG EINES MITTELS, DASS MIT EINEM INTERNALISIERENDEN TAT-PEPTID VERBUNDEN IST, UND EINES ENTZÜNDUNGSHEMMENDEN MITTELS

CO-ADMINISTRATION D'UN AGENT LIÉ À UN PEPTIDE D'INTERNALISATION TAT AVEC UN ANTI-INFLAMMATOIRE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

05.12.2007 US 992678 P

(43)	Date of publication of application:
	22.09.2010 Bulletin 2010/38

(73)	Proprietor: NoNO Inc.
	Toronto ON M8X 1R5 (CA)

(72)	Inventors:
	TYMIANSKI, Michael Toronto Ontario M8X1R5 (CA) GARMAN, Jonathan David Ontario L-4J 8N1 (CA)

(74)	Representative: Green, Mark Charles et al
	Urquhart-Dykes & Lord LLP The Podium 1 Eversholt Street London NW1 2DN London NW1 2DN (GB)

(56)

References cited: :

EP-A1- 2 223 998
WO-A1-2009/015385
WO-A2-01/83547
US-A1- 2003 083 256
US-A1- 2006 148 711

WO-A1-2009/006611
WO-A2-00/34468
US-A1- 2003 050 243
US-A1- 2006 142 181
US-A1- 2007 048 310

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).